Soumerai Jacob D, Barrientos Jacqueline, Ahn Inhye, Coombs Catherine, Gladstone Douglas, Hoffman Marc, Kittai Adam, Jacobs Ryan, Lipsky Andrew, Patel Krish, Rhodes Joanna, Skarbnik Alan, Thompson Meghan, Ermann Daniel, Reville Patrick, Shah Harsh, Brown Jennifer R, Stephens Deborah M
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Mount Sinai Comprehensive Cancer Center, Miami, FL.
Blood Adv. 2025 Mar 11;9(5):1213-1229. doi: 10.1182/bloodadvances.2024014474.
Over the past decade, treatment recommendations for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have shifted from traditional chemoimmunotherapy to targeted therapies. Multiple new therapies are commercially available, and, in many cases, a lack of randomized clinical trial data makes selection of the optimal treatment for each patient challenging. Additionally, many patients continue to receive chemoimmunotherapy in the United States, suggesting a gap between guidelines and real-world practice. The Lymphoma Research Foundation convened a workshop comprising a panel of CLL/SLL experts in the United States to develop consensus recommendations for selection and sequencing of therapies for patients with CLL/SLL in the United States. Herein, the recommendations are compiled for use as a practical clinical guide for treating providers caring for patients with CLL/SLL, which complement existing guidelines by providing a nuanced discussion relating how our panel of CLL/SLL experts in the United States care for patients in a real-world environment.
在过去十年中，慢性淋巴细胞白血病（CLL）或小淋巴细胞淋巴瘤（SLL）患者的治疗建议已从传统的化疗免疫疗法转向靶向疗法。多种新疗法已上市，而且在许多情况下，由于缺乏随机临床试验数据，为每位患者选择最佳治疗方案具有挑战性。此外，在美国，许多患者仍在接受化疗免疫疗法，这表明指南与实际临床实践之间存在差距。淋巴瘤研究基金会召集了一个由美国CLL/SLL专家组成的小组举办了一次研讨会，旨在为美国CLL/SLL患者的治疗选择和排序制定共识性建议。在此，这些建议被汇编成册，作为治疗CLL/SLL患者的医疗服务提供者的实用临床指南，通过提供关于美国CLL/SLL专家小组在实际临床环境中如何治疗患者的细致讨论，对现有指南起到补充作用。
